Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00496379 · ClinicalTrials.gov registry record · Phase 2
ZK219477 (Sagopilone) in Patients With Breast Cancer and Brain Metastases
A Phase 2 study, sponsored by Nancy Lin, MD.
- Terminated
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT00496379 is a Phase 2 study that was terminated before completion, run by Nancy Lin, MD. The registered enrollment target is 15 participants.
The verdict
NCT00496379, a Phase 2 study, was terminated before completion, sponsored by Nancy Lin, MD.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this research study is to determine the effects (good and bad) of ZK219477(sagopilone) on participants and their cancer. ZK219477 is a chemotherapy drug that is thought to work by interfering with the ability of cancer cells to grow and divide. It is a part of a group of drugs called "epothilones" which appear to cause shrinkage of cancer in some patients with breast cancer. It is generally difficult for chemotherapy to enter the brain. However, it is believed that ZK219477 crosses into the brain. We are also studying whether an investigational MRI scan procedure may eventually help to predict which patients will benefit from ZK219477.
Interventions
- DRUG ZK219477
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2007-07 |
| Est. Completion | 2012-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00496379
The ClinicalTrials.gov registry entry for NCT00496379 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nancy Lin, MD, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ZK219477 is the first listed.
NCT00496379 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00496379 about?
NCT00496379 is a clinical study titled "ZK219477 (Sagopilone) in Patients With Breast Cancer and Brain Metastases". The purpose of this research study is to determine the effects (good and bad) of ZK219477(sagopilone) on participants and their cancer. ZK219477 is a chemotherapy drug that is thought to work by interfering with the ability of cancer cells to grow and divide. It is a part of a group of drugs called ...
What is the current status of trial NCT00496379?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2007-07. Estimated completion is 2012-01.
What interventions are being tested in trial NCT00496379?
The interventions under investigation include: ZK219477 (DRUG).
Who is sponsoring clinical trial NCT00496379?
This trial is sponsored by Nancy Lin, MD, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.